ClinicalTrials.gg
Status unknownNCT04286802SMAL-SALTUpdated Feb 27, 2020

Impact of Self-monitoring of Salt Intake by Salt Meter in Hypertensive Patients

An interventional study of Salt-meter and Education in Hypertension and Salt; Excess, sponsored by Mahidol University. Status unknown at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-27.

Sponsored by Mahidol University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2020), so the status shown — last known as Active, not recruiting — may be out of date.

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Jul 2017, registered Feb 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Hypertension is one of the most common chronic medical conditions. The concerned sequelae are the cardiovascular complications, especially acute myocardial infarction and stroke. In Thailand, the incidence of hypertension is increasing each year. Many clinical studies found that salt intake over the reference level (>5 g/day) would result in elevated blood pressure (BP) and long-term morbidity. Dietary salt reduction campaigns were unsuccessful, in part, due to time limitation in the clinic, lacking of awareness, and the higher threshold to detect salt taste in chronic high salt ingestion. Salt meter is a device used to detect sodium content in daily food. It will facilitate monitoring and control of salt intake. The 24-hour urinary sodium excretion is an acceptable method to reflect the quantity of sodium intake. This study aimed to compare the efficacy of salt meter plus dietary education compared with education alone in terms of salt intake reduction, blood pressure, salt taste sensitivity, and vascular consequence.

Read the detailed description

A randomized-controlled trial was conducted in hypertensive patients whose BP was uncontrolled (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg) despite therapy or antihypertensive-naïve. Patients were randomized to receive salt meter to use in conjunction with dietary education (group A) or receive education only (group B), and were followed up for 8 weeks. Dietary education was provided by certified dietician without awareness of patients' allocation. The primary endpoint was change in 24-hour urinary sodium excretion. Changes in BP, salt taste sensitivity threshold, cardio-ankle vascular index (CAVI), as well as motivation to maintain low salt diet were also analyzed.

02

Conditions studied

  • Hypertension
  • Salt; Excess

Browse trials for

Keywords

  • hypertension
  • uncontrolled
  • salt, excess
  • salt meter
03

In context

Hypertension

6,834 studies on the registry are indexed under Hypertension; 971 are open to participants now.

This study's planned enrollment of 100 is above the median of 90 across 5,095 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Mahidol University is the lead sponsor of 744 studies on the registry; 116 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mean SBP 140-179 mmHg or mean DBP 90-109 mmHg (average 3 times)
  • Diagnosed of hypertension for at least 3 months
  • No adjustment of antihypertensive agents for at least 1 month
  • 24h Urine sodium ≥ 90 mmol/day
  • eGFR ≥ 45 ml/min/1.73 sq.m.

Exclusion criteria

Exclusion Criteria:

  • eGFR \< 45 ml/min/1.73 sq.m.
  • UACR > 300 mg/g
  • Serum potassium > 6.0 mmol/l
  • Serum sodium \< 135 mmol/l
  • Unable to collect 24-hour urine
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Salt-meter

    Patients received salt-meter in conjunction with dietary education by trained dietician to help monitoring the salt content in food, as well as usual care by their primary physicians.

    Device: Salt-meter · Behavioral: Education

  • Active comparator
    Control

    Patients received dietary education by trained dietician and usual care by their primary physicians.

    Behavioral: Education

Interventions

  • DeviceSalt-meter

    Salt-meter, developed by Faculty of Engineering at Mahidol University, is a device to measure sodium chloride content in the food and reflects to user with number and symbols for easy-understanding.

  • BehavioralEducation

    Program dietary education by certified dietician who did not know the patients arm allocation.

06

What researchers measure

Primary outcomes

  1. 24-hour urinary sodium excretion

    Change in 24-hour urinary sodium excretion from baseline

    Time frame: 8 weeks

Secondary outcomes

  1. Change in systolic and diastolic blood pressure

    Changes in systolic and diastolic blood pressure from baseline

    Time frame: 8 weeks

  2. Improvement in salt taste sensitivity by evaluating the salt detection or recognition thresholds

    Using the different saline concentration in solution. Starting from the lowest to higher concentration, the point when the patient can differentiate from distilled water is called "detection threshold", and the point that patient can identify salty taste is called "recognition" threshold.

    Time frame: 8 weeks

  3. Change in cardio-ankle vascular index (CAVI)

    Change in cardio-ankle vascular index (CAVI) from baseline

    Time frame: 8 weeks

Other outcomes

  1. Number of patients with hypertensive emergency

    Number of patients documented to have hospitalisation for hypertension treatment including hypertensive emergency requiring intravenous antihypertensive agents.

    Time frame: 8 weeks

  2. Questionnaire about motivation to maintain low salt diet

    Scale from 0 to 10 to estimate self motivation for taking low salt strategy at baseline and at 8 weeks

    Time frame: after 8 weeks

07

Study locations

1 site
  • Faculty of Medicine, Ramathibodi Hospital, Mahidol University
    Bangkok, 10400, Thailand
08

References and documents

Publications

  • Mente A, O'Donnell MJ, Rangarajan S, McQueen MJ, Poirier P, Wielgosz A, Morrison H, Li W, Wang X, Di C, Mony P, Devanath A, Rosengren A, Oguz A, Zatonska K, Yusufali AH, Lopez-Jaramillo P, Avezum A, Ismail N, Lanas F, Puoane T, Diaz R, Kelishadi R, Iqbal R, Yusuf R, Chifamba J, Khatib R, Teo K, Yusuf S; PURE Investigators. Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med. 2014 Aug 14;371(7):601-11. doi: 10.1056/NEJMoa1311989. PubMed 25119606 ↗
  • Cook NR, Kumanyika SK, Cutler JA, Whelton PK; Trials of Hypertension Prevention Collaborative Research Group. Dose-response of sodium excretion and blood pressure change among overweight, nonhypertensive adults in a 3-year dietary intervention study. J Hum Hypertens. 2005 Jan;19(1):47-54. doi: 10.1038/sj.jhh.1001775. PubMed 15343354 ↗
  • MacGregor GA, Markandu ND, Sagnella GA, Singer DR, Cappuccio FP. Double-blind study of three sodium intakes and long-term effects of sodium restriction in essential hypertension. Lancet. 1989 Nov 25;2(8674):1244-7. doi: 10.1016/s0140-6736(89)91852-7. PubMed 2573761 ↗
  • Piovesana Pde M, Sampaio Kde L, Gallani MC. Association between Taste Sensitivity and Self-Reported and Objective Measures of Salt Intake among Hypertensive and Normotensive Individuals. ISRN Nutr. 2012 Oct 24;2013:301213. doi: 10.5402/2013/301213. eCollection 2013. PubMed 24967247 ↗
  • Kusaba T, Mori Y, Masami O, Hiroko N, Adachi T, Sugishita C, Sonomura K, Kimura T, Kishimoto N, Nakagawa H, Okigaki M, Hatta T, Matsubara H. Sodium restriction improves the gustatory threshold for salty taste in patients with chronic kidney disease. Kidney Int. 2009 Sep;76(6):638-43. doi: 10.1038/ki.2009.214. Epub 2009 Jun 10. PubMed 19516246 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2017 (actual). Primary completion is estimated for Feb 2020, 31 months after the start.

Of 1,339 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 42. This study's planned 31 months is above that.

Counting every sponsor, half of 1,433 studies reached it within 23 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2020
First posted
Feb 27, 2020
StartActual
Jul 11, 2017
Primary completionEst.
Feb 21, 2020
CompletionEst.
Feb 28, 2020
Last update
Feb 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04286802
Lead sponsor
Mahidol University
Responsible party
Sponsor
First posted
Feb 27, 2020
Start date
Jul 11, 2017
Primary completion
Feb 21, 2020 (estimated)
Completion
Feb 28, 2020 (estimated)
Last update
Feb 27, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion